SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Anavekar, N. S
Right arrow Articles by Solomon, S. D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anavekar, N. S
Right arrow Articles by Solomon, S. D
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Angiotensin II receptor blockade and ventricular remodelling

Nagesh S Anavekar

Wynn Metabolic Cardiology Unit, Baker Heart Institute, Melbourne, Australia

Scott D Solomon

Division of Cardiovascular Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, USA, ssolomon{at}rics.bwh.harvard.edu

Cardiac remodelling is the expression of molecular, cellular and interstitial changes in response to cardiac injury, manifesting as adverse alterations in the size, shape and function of the ventricle. Several clinical studies have documented significant elevations in the levels of renin, angiotensin II (Ang II) and aldosterone attending acute myocardial infarction and/or congestive heart failure. Similar to catecholamines, markedly elevated activity of the renin-angiotensin-aldosterone system (RAAS) is associated with poor prognosis. The effects of Ang II upon cardiac tissue are related to two primary receptors, Ang II type 1 (AT 1) and Ang II type 2 (AT2). The AT1-receptor appears to mediate many of the deleterious effects of chronic RAAS activity, while the AT2-receptor is increasingly shown to have potential cardioprotective effects. Attenuating the deleterious effects of sustained Ang II stimulation can be achieved by direct inhibition of angiotensin-converting enzyme (ACE) and/or direct antagonism of AT receptors. ACE inhibition reduces left ventricular (LV) volumes, retards the progression of LV dilatation and hypertrophy and increases systolic function in systolic dysfunction. By blocking at the receptor level, Ang II receptor blockers (ARBs) provide an alternative and more direct approach to inhibiting the effects of Ang II; however, data relating to their effects upon ventricular remodelling, whether used in isolation or in combination with ACE inhibitors (ACE-Is), are less convincing. Data arising from several recent clinical trials suggest that simultaneous use of ACE-Is and ARBs maybe of more benefit in attenuating ventricular remodelling than either agent alone.

Key Words: remodelling • angiotensin receptor blockers • ACE inhibitors • ventricle • angiotensin II • clinical trials

References

  • Cohn JN, Ferrari R., Sharpe N. et al. Cardiac remodeling: Concepts and clinical implications. J Am Coll Cardiol 2000;35: 569-82.[Abstract/Free Full Text]
  • McKay RG, Pfeffer MA, Pasternak RC et al. Left ventricular remodeling following myocardial infarction: A corollary to infarct expansion. Circulation 1986;74:693-8.[Abstract/Free Full Text]
  • Eaton LW, Buckley BH Expansion of acute myocardial infarction: its relationship to infarct morphology in the canine model. Circ Res 1981;49:80-8.[Free Full Text]
  • Hochman JS, Buckley BH Expansion of acute myocardial infarction: an experimental study. Circulation 1982;65:1446-50. 5. Pfeffer JM, Pfeffer MA, Fletcher PJ, Braunwald E. Progressive ventricular remodeling in the rat with myocardial infarction. Am J Physiol 1991;260:H1401.
  • Francis GS, Benedict C.,Johnstone DE et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction, with and without congestive cardiac failure. Circulation 1990:82:1724-9.[Abstract/Free Full Text]
  • Cohn JN, Levine TB, Olivari MT et al. Plasma norepinephrine as a guide to prognosis in patients with congestive cardiac failure. N Engl J Med 1984;311:819-23.[Abstract]
  • Vantrimpont P., Rouleau J., Ciampi A. et al.Two-year course and significance of neurohormonal activation in Survival and Ventricular Enlargement (SAVE) study. Eur Heart J 1998;19: 1552-663.[Abstract/Free Full Text]
  • Levine B., Kalman J., Mayer L. et al. Elevated circulating levels of tumor necrosis factor in severe heart failure. N Engl J Med 1990;323:236-41.[Abstract]
  • McMurray JJ, Ray SG, Abdullah I., Darjie HJ, Morton JJ Plasma endothelin in chronic heart failure. Circulation 1992; 85:1374-9.[Abstract/Free Full Text]
  • McClure S., Carunana L., Davis AP et al. Cohort study of naturetic peptides for identifying left ventricular systolic dysfunction in primary care. BMJ 1998;317:516-19.[Abstract/Free Full Text]
  • Torre-Aminone G., Kapadia S., Benedict C., Oral H., Young JB, Mann DB Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the SOLVD study. J Am Coll Cardiol 1996;27:1201-06.[Abstract]
  • Swynghedauw B. Myocardial remodeling: pharmacological targets. Expert Opin Investig Drugs 2002;11:661-74.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Korup E., Dalsgaard D., Nyvad O., Jensen TM,Toft E., Berning J. Comparisons of degrees of left ventricular dilatation within 3 hours and up to 6 days following first acute myocardial infarction. Am J Cardiol 1997; 80:447-52.
  • Olivetti G., Capasso JM, Meggs LG et al. Cellular basis of chronic ventricular remodeling in rats. Circ Res 1991;68:856-61.[Abstract/Free Full Text]
  • Anversa P., Olivetti G., Capasso JM Cellular basis of ventricular remodeling after myocardial infarction. Am J Cardiol 1991;68:7D-16D.[Medline] [Order article via Infotrieve]
  • Mitchell GF, Lamas GA, Vaughan DE, Pfeffer MA Left ventricular remodeling in the year after first anterior myocardial infarction. J Am Coll Cardiol 1992;19:1136-442.[Abstract]
  • White HD, Norris RM, Brown MA et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44-8.[Abstract/Free Full Text]
  • St John Sutton, Lee D., Rouleau JL Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation 2003;107:2577-82.[Abstract/Free Full Text]
  • Opie LH Angiotensin converting enzyme inhibitors. University of Cape Town Press. 3rd edition.
  • Campbell DJ Circulating and tissue angiotensin systems. J Clin Invest 1987;79:1-7.[Web of Science][Medline] [Order article via Infotrieve]
  • Timmermans P., Benfield P., Chiu AT Angiotensin II receptors and functional correlates. Am J Hypertens 1992;5:221-35.
  • Clauser E. Molecular structure and function of angiotensin II receptors. Nephrologie 1998;19:403-10.[Web of Science][Medline] [Order article via Infotrieve]
  • De Mello WC, Jan Danser AHAngiotensin II and the heart. Hypertension 2000;35:1183-8.[Abstract/Free Full Text]
  • Iwai N., Shimoike H., Kinoshita M. Cardiac renin-angiotensin system in the hypertrophied heart. Circulation 1995;92:2690-6.[Abstract/Free Full Text]
  • Matsubara H. Pathophysiological role of angiotensin II receptor in cardiac and renal diseases. Circ Res 1998;83:1182-91.[Abstract/Free Full Text]
  • Tsuchida S., Matsuaka T., Chen X. et al. Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensiogen nullizygotes. J Clin Invest 1998;101:755-60.[Web of Science][Medline] [Order article via Infotrieve]
  • Haranwaki M., Coffman TM, Lasbus A. et al. Pressure overload hypertrophy is unabated in mice devoid of AT1A receptors. Am J Physiol 1998;274:868-73.
  • Sadoshima J., Izumo S. Molecular characterization of angiotensin II induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: critical role of the AT1 receptor subtype. Circ Res 1993;73:413-23.[Abstract/Free Full Text]
  • Studer R., Reinecke H., Muller B. et al. Increased angiotensin I converting enzyme gene expression in the failing human heart. J Clin Invest 1994;94:301-10.[Web of Science][Medline] [Order article via Infotrieve]
  • Wharton J., Morgan K., Rutherford RAD et al. Differential distribution of AT2 receptors in the normal and failing human heart. J Pharmacol Exp Ther 1998;284:323-36.[Abstract/Free Full Text]
  • Horuichi M., Akshita M., Dzau VJ Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999;33:613-21.[Abstract/Free Full Text]
  • Lehtonen JA, Horuichi M., Dzau VJ Ceramide as a second messenger for angiotensin II type 2 receptor mediated apoptosis. Circulation 1997;96(suppl):554-65.[Web of Science]
  • Booz GW, Baker KM Role of type 1 and type 2 angiotensin receptors in angiotensin II induced cardiomyocyte hypertrophy. Hypertension 1996;28:635-40.[Abstract/Free Full Text]
  • Tsutsumi Y., Matsubara H., Ohkubo N. et al. Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circ Res 1998;83:1035-46.[Abstract/Free Full Text]
  • Jin XQ, Fukuda N., Su JZ et al.Angiotensin II type 2 receptor gene transfer downregulates angiotensin II type 1a receptor in vascular smooth muscle cells. Hypertension 2002;39:1021-7.[Abstract/Free Full Text]
  • Oishi Y., Ozono R.,Yano Y. et al.Cardioprotective role of AT2 receptor in postinfarction left ventricular remodeling. Hypertension 2003;41[Part II]:814-18.[Abstract/Free Full Text]
  • Tsutsumi Y., Matsubara H., Masaki H. et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999; 104:925-35.[Web of Science][Medline] [Order article via Infotrieve]
  • Carey RM, Wang ZQ, Siragy HM Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000;35:155-63.[Abstract/Free Full Text]
  • Swedberg K., Held P., Kjekshus J. et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327:678-84.[Abstract]
  • Kober L., Torp-Pederson C., Carlsen JE et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-6.[Abstract/Free Full Text]
  • Pfeffer MA ACE inhibition in acute myocardial infarction. N Engl Med 1995;332:118-20.[Free Full Text]
  • Dickstein K., Kjekshus J.; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Lancet 2002;360:752-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pitt B., Poole-Wilson PA, Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial - The Losartan Heart Failure Survival Study (ELITE II). Lancet 2000;355:1582-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cohn JN, Tognoni G.; Valsartan Heart Failure Trial Investigators. A randomised trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-75.[Abstract/Free Full Text]
  • Pfeffer MA, Swedberg K., Granger CB et al. Effects of candersartan on mortality and morbidity in patients with chronic heart failure: the CHARM overall programme. Lancet 2003; 362:759-66.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pfeffer MA, McMurray JJV,Velazquez E. et al. Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both. N Engl J Med 2003;349:1893-906.[Abstract/Free Full Text]
  • McDonald KM, Garr MD, Carlyle PF et al. Relative effects of {alpha}1 adrenoreceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype I receptor blockade on ventricular remodeling in the dog. Circulation 1994;90:3034-46.[Abstract/Free Full Text]
  • Taylor K., Patten RD, Smith JJ et al. Divergent effects of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism on myocardial cellular proliferation and collagen deposition after myocardial infarction in rats. J Cardiovasc Pharmacol 1998;31:654-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Spinale FG, de Gasparo M., Whitebread S. et al. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing -induced heart failure: effects on left ventricular performance and neurohormonal systems. Circulation 1997;96:2385-96.[Abstract/Free Full Text]
  • Konstam MA, Patten RD,Thomas I. et al. Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: Results of the ELITE ventricular function substudy. Am Heart J 2000;139:1081-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • McKelvie RS,Yusuf S.,Azezum A. et al. Comparison of candersartan, enalapril, and their combination in congestive heart failure. Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Circulation 1999;100: 1056-64.[Abstract/Free Full Text]
  • McKelvie RS, Rouleau JL, White M. et al. Comparative effect of enalapril, candersartan or metoprolol alone or in combination on ventricular remodeling in patients with congestive heart failure. European Heart Journal 2003;24:1727-34.[Abstract/Free Full Text]
  • Moller JE, Dahlstrom U., Gotzsche O. et al. Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL). Am Heart J 2004:147;494-501.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Solomon SD, Skali HS,Anavekar NS et al. Changes in ventricular size and function in patients treated with valsartan, captopril, or both following myocardial infarction. (Abstract). European Society of Cardiology, August 2004.

Journal of Renin-Angiotensin-Aldosterone System, Vol. 6, No. 1, 43-48 (2005)
DOI: 10.3317/jraas.2005.006
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 CirculationHome page
P. Verdecchia, P. Sleight, G. Mancia, R. Fagard, B. Trimarco, R. E. Schmieder, J.-H. Kim, G. Jennings, P. Jansky, J.-H. Chen, et al.
Effects of Telmisartan, Ramipril, and Their Combination on Left Ventricular Hypertrophy in Individuals at High Vascular Risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease
Circulation, October 6, 2009; 120(14): 1380 - 1389.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Anavekar, N. S
Right arrow Articles by Solomon, S. D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anavekar, N. S
Right arrow Articles by Solomon, S. D
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement